These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 3705895)

  • 21. [High-dose cytosine arabinoside therapy in refractory acute leukemia].
    Yorimitsu S; Takahashi I; Kitazima K; Kimura I; Hara M; Tokuda M
    Rinsho Ketsueki; 1984 Dec; 25(12):1941-6. PubMed ID: 6533329
    [No Abstract]   [Full Text] [Related]  

  • 22. [Retrospective study of 30 cases of myelodysplastic syndrome according to the French-American-British classification].
    Piguet D; Schmidt PM; Delacrétaz F; Mermillod B
    Schweiz Med Wochenschr; 1987 Jan; 117(2):61-6. PubMed ID: 3468610
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemotherapy for adult acute nonlymphocytic leukemia with daunorubicin and cytosine arabinoside.
    Cassileth PA; Katz ME
    Cancer Treat Rep; 1977 Nov; 61(8):1441-5. PubMed ID: 922749
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of low-dose 1-beta-D-arabinofuranosylcytosine given by continuous intravenous infusion over twenty-one days.
    Kreis W; Chaudhri F; Chan K; Allen S; Budman DR; Schulman P; Weiselberg L; Freeman J; Deere M; Vinciguerra V
    Cancer Res; 1985 Dec; 45(12 Pt 1):6498-501. PubMed ID: 3864533
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-dose cytosine arabinoside as consolidation chemotherapy for acute nonlymphocytic leukemia in remission.
    Urabe A; Mizoguchi H; Hoshino S; Nomura T; Dan K; Toyama K; Kimura M; Ogawa T; Yamaguchi H; Mutoh Y
    Int J Hematol; 1991 Feb; 54(1):75-7. PubMed ID: 1954354
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of refractory leukemia with high-dose cytosine arabinoside.
    Klener P; Háber J
    Neoplasma; 1985; 32(1):113-7. PubMed ID: 3856754
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of small doses cytosine arabinoside (Ara-C) on leukemic cells in vitro and in vivo. Results in patients with leukemia and myelodysplastic syndrome.
    Kuliczkowski K; Kotlerek-Haus S; Frydecka I; Sedek K; Nowicka J
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(6):738-48. PubMed ID: 2436986
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aclarubicin in the treatment of acute nonlymphocytic leukemia refractory to treatment with daunorubicin and cytarabine: a phase II trial.
    Pedersen-Bjergaard J; Brincker H; Ellegaard J; Drivsholm A; Freund L; Jensen KB; Jensen MK; Nissen NI
    Cancer Treat Rep; 1984 Oct; 68(10):1233-8. PubMed ID: 6597002
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemotherapy for acute non-lymphocytic leukemia with low-dose cytosine arabinoside (Ara-C).
    Lin SF; Liu HW; Chen TP
    Nihon Ketsueki Gakkai Zasshi; 1990 Feb; 53(1):45-50. PubMed ID: 2330805
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Intermediate-dose cytosine arabinoside therapy in refractory acute leukemia].
    Ohshima A; Yoshida K; Miyazaki S; Fukushima Y; Miura AB; Endo K; Ando H; Sasaki H; Saito S; Sato I
    Gan To Kagaku Ryoho; 1989 Jan; 16(1):139-42. PubMed ID: 2643393
    [No Abstract]   [Full Text] [Related]  

  • 31. Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia.
    Giles F; Verstovsek S; Thomas D; Gerson S; Cortes J; Faderl S; Ferrajoli A; Ravandi F; Kornblau S; Garcia-Manero G; Jabbour E; O'Brien S; Karsten V; Cahill A; Yee K; Albitar M; Sznol M; Kantarjian H
    Clin Cancer Res; 2005 Nov; 11(21):7817-24. PubMed ID: 16278404
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Remission of hypoplastic acute leukemia by low dose Ara-C: one case report.
    Wei SY; Lin SF; Chen TP; Liu HW; Chang CS; Lin TC
    Gaoxiong Yi Xue Ke Xue Za Zhi; 1991 Oct; 7(10):531-5. PubMed ID: 1811073
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
    Gandhi V; Estey E; Du M; Keating MJ; Plunkett W
    Clin Cancer Res; 1997 Sep; 3(9):1539-45. PubMed ID: 9815841
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: an update.
    Wolff SN; Herzig RH; Phillips GL; Lazarus HM; Greer JP; Stein RS; Ray WA; Herzig GP
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):12-7. PubMed ID: 3589687
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined low-dose cytarabine, melphalan and mitoxantrone for older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.
    Yamauchi T; Negoro E; Arai H; Ikegaya S; Takagi K; Takemura H; Inai K; Yoshida A; Urasaki Y; Iwasaki H; Ueda T
    Anticancer Res; 2007; 27(4C):2635-9. PubMed ID: 17695426
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [High doses of cytosine arabinoside in the treatment of patients with acute relapsing or refractory leukemia].
    Lobato-Mendizábal E; Ruiz-Argüelles GJ; Marín-López A
    Rev Invest Clin; 1989; 41(2):139-45. PubMed ID: 2675236
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [High-dose cytosine arabinoside treatment of leukemia with special reference to the optimal number of doses].
    Sampi K; Maseki N; Kumai R; Kaneko Y; Sakurai M; Hattori M
    Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2595-8. PubMed ID: 2774589
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low-dose cytarabine: persistence of a clonal abnormality during complete remission of acute nonlymphocytic leukemia.
    Tilly H; Bastard C; Bizet M; Piguet H; Castaigne S; Degos L
    N Engl J Med; 1986 Jan; 314(4):246-7. PubMed ID: 3941713
    [No Abstract]   [Full Text] [Related]  

  • 39. [Experiences with low-dos Ara-C in the therapy of hematological neoplasms].
    Jacky E; Frick P
    Ther Umsch; 1988 Feb; 45(2):119-23. PubMed ID: 3358244
    [No Abstract]   [Full Text] [Related]  

  • 40. [High doses of ARA C in the treatment of acute leukemia].
    Lobato-Mendizábal E; Ruiz-Argüelles GJ; Marín-López A
    Sangre (Barc); 1989 Feb; 34(1):78-9. PubMed ID: 2711290
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.